Clinical pancreatic islet transplantation can be considered one of the safest and least
invasive transplant procedures. Remarkable progress has occurred in both the technical …

Pancreatic islet transplantation has become an established approach to β-cell replacement
therapy for the treatment of insulin-deficient diabetes. Recent progress in techniques for islet …

We report the 1-year results from one patient as the preliminary analysis of a first-in-human
phase I clinical trial (ChiCTR2300072200) assessing the feasibility of autologous …

Background The introduction of solid-phase immunoassay (SPI) technology for the detection
and characterization of human leukocyte antigen (HLA) antibodies in transplantation while …

Successful strategies for treating type 1 diabetes need to restore the function of pancreatic
beta cells that are destroyed by the immune system and overcome further destruction of …

Alloantibodies directed against HLA antigens, are a barrier to long-term solid organ allograft
survival. The clinical impact of preformed, donor-directed HLA alloantibodies range from …

The advancement and improvement in decellularization methods can be attributed to the
increasing demand for tissues and organs for transplantation. Decellularized tissues and …

Background. The applicability of islet transplantation as treatment for type 1 diabetes is
limited by long-term graft dysfunction, immunosuppressive drug toxicity, need for multiple …

Until recently, allograft rejection was thought to be mediated primarily by alloreactive T cells.
Consequently, immunosuppressive approaches focused on inhibition of T cell activation …

Human Leukocyte Antigen (HLA) antibodies posttransplant have been associated with an
increased risk of early graft failure in kidney transplants. Whether this also applies to islet …